[
    [
        {
            "time": "2023-03-15",
            "original_text": "AbbVie Inflated Prices For Two Major Drugs, Engaged In Anticompetitive Practices, House Oversight Report Says",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Inflated Prices",
                    "Anticompetitive Practices",
                    "House Oversight Report"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie Inflated Prices For Two Major Drugs, Engaged In Anticompetitive Practices, House Oversight Report Says",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-03-16",
            "original_text": "House Committee Takes On Pricing, Patents for Top-Selling Drug Humira",
            "features": {
                "keywords": [
                    "House Committee",
                    "Pricing",
                    "Patents",
                    "Humira"
                ],
                "sentiment_score": -0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "House Committee Takes On Pricing, Patents for Top-Selling Drug Humira",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-03-17",
            "original_text": "U.S. lawmakers request federal inquiry into AbbVie's actions with drug Humira -statement",
            "features": {
                "keywords": [
                    "U.S. lawmakers",
                    "federal inquiry",
                    "AbbVie",
                    "Humira"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "U.S. lawmakers request federal inquiry into AbbVie's actions with drug Humira -statement",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-03-18",
            "original_text": "AbbVie Slammed in House Report for Pricing Practices. Market Shrugs.",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Slammed",
                    "House Report",
                    "Pricing Practices",
                    "Market Shrugs"
                ],
                "sentiment_score": -0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Slammed in House Report for Pricing Practices. Market Shrugs.",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 7,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-03-19",
            "original_text": "UPDATE 3-Lawmakers say AbbVie exploits U.S. patents to protect Humira profits, price hikes",
            "features": {
                "keywords": [
                    "Lawmakers",
                    "AbbVie",
                    "Exploits",
                    "U.S. patents",
                    "Humira",
                    "Profits",
                    "Price Hikes"
                ],
                "sentiment_score": -0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "UPDATE 3-Lawmakers say AbbVie exploits U.S. patents to protect Humira profits, price hikes",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-03-20",
            "original_text": "After a Blowout Quarter, Is AbbVie Stock a Buy?",
            "features": {
                "keywords": [
                    "Blowout Quarter",
                    "AbbVie Stock",
                    "Buy"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "After a Blowout Quarter, Is AbbVie Stock a Buy?",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-03-21",
            "original_text": "AbbVie exploits U.S. patents to protect profits: Congress report",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Exploits",
                    "U.S. patents",
                    "Protect Profits",
                    "Congress Report"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie exploits U.S. patents to protect profits: Congress report",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]